Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies

@inproceedings{Chen2016NovelAC,
  title={Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies},
  author={Kevin H. Chen and Masayuki Wada and Amelia E. Firor and Kevin G. Pinz and A Jares and Hua Liu and Huda Salman and Marc G. Golightly and Fengshuo Lan and Xun Jiang and Yupo Ma},
  booktitle={Oncotarget},
  year={2016}
}
Peripheral T-cell lymphomas (PTCLS) comprise a diverse group of difficult to treat, very aggressive non-Hodgkin's lymphomas (NHLS) with poor prognoses and dismal patient outlook. Despite the fact that PTCLs comprise the majority of T-cell malignancies, the standard of care is poorly established. Chimeric antigen receptor (CAR) immunotherapy has shown in B-cell malignancies to be an effective curative option and this extends promise into treating T-cell malignancies. Because PTCLS frequently… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Advantages and applications of CAR-expressing natural killer cells

Front. Pharmacol. • 2015
View 14 Excerpts
Highly Influenced

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.

Journal of the National Cancer Institute • 2016
View 1 Excerpt

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.

Molecular therapy : the journal of the American Society of Gene Therapy • 2015
View 1 Excerpt

CD 19 - CAR trials

K Pinz, H Liu, +8 authors Y Ma
Cancer journal • 2014

Similar Papers

Loading similar papers…